IL DONG PHARMACEUTICAL CO., LTD. Unconfirmed response to report on sale of control of affiliate ILIAD BMS
IAI summary · Not investment advice
Ildong Pharmaceutical said it is reviewing a report on selling control of affiliate Iliad BMS but nothing is decided, and will update by December 11, 2026.
Key facts
- Clarification type
- Undetermined
- Report
- Ildong Pharmaceutical reportedly pursuing sale of management control of iLeadBMS, its new drug development affiliate
- Company statement
- The company is reviewing various possibilities regarding its affiliate iLeadBMS from multiple angles, and nothing specific has been decided so far.
- Next disclosure date
- Dec 11, 2026Re-disclosure when details are confirmed or within 1 month
- Media outlet
- Seoul Economic Daily
- Report date
- Nov 11, 2026
Commentary
AI commentary · Not investment advice
What happened
Ildong Pharmaceutical responded to a Seoul Economic Daily report. The report said the company was seeking to sell management control of its affiliate Ilead BMS, a drug development company. The company said it is reviewing several possibilities from many angles. It said nothing specific has been decided so far.
In the company's terms
The company's answer is classified as "undetermined". This means it has neither confirmed nor denied the report.
What changes for shareholders
The company set December 11, 2026 as the date to disclose again. If the matter is decided before then, it will disclose again at that point. If not, it will update within 1 month.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist